{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=All&page=15",
    "query": {
      "condition": "All",
      "page": 15
    },
    "page_size": 10
  },
  "pagination": {
    "page": 15,
    "page_size": 10,
    "total_count": 2204,
    "total_pages": 221,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=All&page=16&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=All&page=14&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-24T12:53:47.767Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00004105",
      "title": "Combination Chemotherapy in Treating Patients With Advanced Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Leukemia",
        "Lymphoma",
        "Sarcoma",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "estramustine phosphate sodium",
          "type": "DRUG"
        },
        {
          "name": "paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "vinorelbine ditartrate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "1998-09",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2011-03-28",
      "last_synced_at": "2026-10-24T12:53:47.767Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00004105"
    },
    {
      "nct_id": "NCT00664677",
      "title": "Phase 1 Study of Terameprocol (EM-1421) in Patients With Leukemia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Leukemias",
        "Acute Myeloid Leukemia (AML)",
        "Acute Lymphocytic Leukemia (ALL)",
        "Adult T Cell Leukemia (ATL)",
        "Chronic Myeloid Leukemia (CML-BP)",
        "Chronic Lymphocytic Leukemia (CLL)",
        "Myelodysplastic Syndrome (MDS)",
        "Chronic Myelomonocytic Leukemia (CMML)"
      ],
      "interventions": [
        {
          "name": "Terameprocol (EM-1421)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Erimos Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2007-08",
      "completion_date": "2009-06",
      "has_results": false,
      "last_update_posted_date": "2016-02-23",
      "last_synced_at": "2026-10-24T12:53:47.767Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00664677"
    },
    {
      "nct_id": "NCT00061945",
      "title": "Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Acute Undifferentiated Leukemia",
        "B-cell Adult Acute Lymphoblastic Leukemia",
        "B-cell Childhood Acute Lymphoblastic Leukemia",
        "L1 Adult Acute Lymphoblastic Leukemia",
        "L1 Childhood Acute Lymphoblastic Leukemia",
        "L2 Adult Acute Lymphoblastic Leukemia",
        "L2 Childhood Acute Lymphoblastic Leukemia",
        "Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia",
        "Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia",
        "Philadelphia Chromosome Positive Childhood Precursor Acute Lymphoblastic Leukemia",
        "T-cell Adult Acute Lymphoblastic Leukemia",
        "T-cell Childhood Acute Lymphoblastic Leukemia",
        "Untreated Adult Acute Lymphoblastic Leukemia",
        "Untreated Childhood Acute Lymphoblastic Leukemia"
      ],
      "interventions": [
        {
          "name": "allopurinol",
          "type": "DRUG"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "daunorubicin hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "vincristine sulfate",
          "type": "DRUG"
        },
        {
          "name": "dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "asparaginase",
          "type": "DRUG"
        },
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "imatinib mesylate",
          "type": "DRUG"
        },
        {
          "name": "methotrexate",
          "type": "DRUG"
        },
        {
          "name": "cytarabine",
          "type": "DRUG"
        },
        {
          "name": "trimethoprim-sulfamethoxazole",
          "type": "DRUG"
        },
        {
          "name": "mercaptopurine",
          "type": "DRUG"
        },
        {
          "name": "leucovorin calcium",
          "type": "DRUG"
        },
        {
          "name": "alemtuzumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "acyclovir",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "15 Years and older"
      },
      "enrollment_count": 302,
      "start_date": "2003-06",
      "completion_date": "2012-10",
      "has_results": true,
      "last_update_posted_date": "2022-05-03",
      "last_synced_at": "2026-10-24T12:53:47.767Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00061945"
    },
    {
      "nct_id": "NCT00114257",
      "title": "Decitabine and FR901228 in Treating Patients With Relapsed or Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative Disorders",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chronic Myeloproliferative Disorders",
        "Leukemia",
        "Myelodysplastic Syndromes",
        "Myelodysplastic/Myeloproliferative Neoplasms"
      ],
      "interventions": [
        {
          "name": "decitabine",
          "type": "DRUG"
        },
        {
          "name": "romidepsin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2005-05",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-02-11",
      "last_synced_at": "2026-10-24T12:53:47.767Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00114257"
    },
    {
      "nct_id": "NCT04357041",
      "title": "COVID-19 Survey Study on Dietary Intake, Physical Activity and Overall Well-being",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "ALL, Adult"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Clinical Nutrition Research Center, Illinois Institute of Technology",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 440,
      "start_date": "2020-04-17",
      "completion_date": "2021-07-31",
      "has_results": false,
      "last_update_posted_date": "2023-05-17",
      "last_synced_at": "2026-10-24T12:53:47.767Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04357041"
    },
    {
      "nct_id": "NCT01116154",
      "title": "Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Adult Nasal Type Extranodal NK/T-cell Lymphoma",
        "Anaplastic Large Cell Lymphoma",
        "Angioimmunoblastic T-cell Lymphoma",
        "Cutaneous B-cell Non-Hodgkin Lymphoma",
        "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue",
        "Hepatosplenic T-cell Lymphoma",
        "Intraocular Lymphoma",
        "Nodal Marginal Zone B-cell Lymphoma",
        "Peripheral T-Cell Lymphoma",
        "Post-transplant Lymphoproliferative Disorder",
        "Recurrent Adult Burkitt Lymphoma",
        "Recurrent Adult Diffuse Large Cell Lymphoma",
        "Recurrent Adult Diffuse Mixed Cell Lymphoma",
        "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma",
        "Recurrent Adult Grade III Lymphomatoid Granulomatosis",
        "Recurrent Adult Hodgkin Lymphoma",
        "Recurrent Adult Immunoblastic Large Cell Lymphoma",
        "Recurrent Adult Lymphoblastic Lymphoma",
        "Recurrent Adult T-cell Leukemia/Lymphoma",
        "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma",
        "Recurrent Grade 1 Follicular Lymphoma",
        "Recurrent Grade 2 Follicular Lymphoma",
        "Recurrent Grade 3 Follicular Lymphoma",
        "Recurrent Mantle Cell Lymphoma",
        "Recurrent Marginal Zone Lymphoma",
        "Recurrent Mycosis Fungoides/Sezary Syndrome",
        "Recurrent Small Lymphocytic Lymphoma",
        "Small Intestine Lymphoma",
        "Splenic Marginal Zone Lymphoma",
        "Testicular Lymphoma",
        "Waldenstrom Macroglobulinemia"
      ],
      "interventions": [
        {
          "name": "lenalidomide",
          "type": "DRUG"
        },
        {
          "name": "vorinostat",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2010-05",
      "completion_date": "2010-08",
      "has_results": false,
      "last_update_posted_date": "2010-12-09",
      "last_synced_at": "2026-10-24T12:53:47.767Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01116154"
    },
    {
      "nct_id": "NCT07219277",
      "title": "Clinical Validation of Early Detection Blood Test for Universal Large-scale Breast Cancer Screening",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Breast Cancer, Liquid Biopsy, Early Detection"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Syantra Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "75 Years",
        "sex": "FEMALE",
        "summary": "30 Years to 75 Years · Female only"
      },
      "enrollment_count": 2000,
      "start_date": "2026-01-07",
      "completion_date": "2027-06-14",
      "has_results": false,
      "last_update_posted_date": "2026-03-11",
      "last_synced_at": "2026-10-24T12:53:47.767Z",
      "location_count": 2,
      "location_summary": "Phoenix, Arizona • New York, New York",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07219277"
    },
    {
      "nct_id": "NCT00469729",
      "title": "Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Hematologic Malignancies",
        "Acute Myeloid Leukemia",
        "Lymphoid Leukemia",
        "Chronic Myeloid Leukemia",
        "Hodgkin's Disease",
        "Non-Hodgkin's Lymphoma",
        "Myelodysplastic Syndromes"
      ],
      "interventions": [
        {
          "name": "StemEx®",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gamida Cell -Teva Joint Venture Ltd.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "12 Years to 55 Years"
      },
      "enrollment_count": 101,
      "start_date": "2007-10",
      "completion_date": "2015-06",
      "has_results": false,
      "last_update_posted_date": "2015-07-10",
      "last_synced_at": "2026-10-24T12:53:47.767Z",
      "location_count": 16,
      "location_summary": "Los Angeles, California • Orange, California • Aurora, Colorado + 10 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Maywood",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00469729"
    },
    {
      "nct_id": "NCT00003572",
      "title": "Total-Body Irradiation, Tacrolimus, and Mycophenolate Mofetil Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Leukemia",
        "Lymphoma",
        "Multiple Myeloma and Plasma Cell Neoplasm",
        "Myelodysplastic Syndromes"
      ],
      "interventions": [
        {
          "name": "peripheral blood lymphocyte therapy",
          "type": "BIOLOGICAL"
        },
        {
          "name": "mycophenolate mofetil",
          "type": "DRUG"
        },
        {
          "name": "tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "allogeneic bone marrow transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 20,
      "start_date": "1998-08",
      "completion_date": "2002-04",
      "has_results": false,
      "last_update_posted_date": "2014-05-02",
      "last_synced_at": "2026-10-24T12:53:47.767Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003572"
    },
    {
      "nct_id": "NCT00053157",
      "title": "Sargramostim in Reducing Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplantation for Hematologic Cancer or Aplastic Anemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Chronic Myeloproliferative Disorders",
        "Graft Versus Host Disease",
        "Leukemia",
        "Lymphoma",
        "Myelodysplastic Syndromes",
        "Myelodysplastic/Myeloproliferative Neoplasms"
      ],
      "interventions": [
        {
          "name": "sargramostim",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Roswell Park Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "5 Years to 60 Years"
      },
      "enrollment_count": 10,
      "start_date": "2002-06",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2022-10-05",
      "last_synced_at": "2026-10-24T12:53:47.767Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00053157"
    }
  ]
}